Heparin seems to be effective in ameliorating pregnancy outcome in thrombophilic women with previous recurrent pregnancy loss, preeclampsia, intrauterine growth restriction and sudden fetal death. A prophylactic effect of heparin treatment has also been proposed in terms of prevention of adverse pregnancy outcomes recurrence in women with history of recurrent miscarriage, severe preeclampsia, placental abruption, low neonatal birth weight and intrauterine fetal death not related to thrombophilia, although literature in this field is quite controversial. The molecular mechanisms by which heparin might exert its potential therapeutic effects in human reproduction are still not fully understood. In this article we review the current knowledge in this research field, focusing on in vitro evidences of heparin's mechanisms of action in the processes of embryo implantation and trophoblast invasion.
GreerIHuntBJ. Low molecular weight heparin in pregnancy: current issues. Br J Haematol. 2005; 128(5): 593-601.
2.
TincaniABranchWLevyRA. Treatment of pregnant patients with antiphospholipid syndrome. Lupus. 2003; 12(7): 524-529.
3.
EmpsonMLassereMCraigJScottJ. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005; 18(2): CD002859.
4.
BrennerBHoffmanRBlumenfeldZ. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost. 2000; 83(5): 693-697.
5.
BrennerB. Enoxaparin treatment improves the gestational outcome of pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. Blood. 2003; 102(11): 43A.
6.
GrisJCMercierEQuereI. Low molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004; 103(10): 3695-3699.
7.
CarpHDolitzkyMInbalA. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost. 2003; 1(3): 433-438.
8.
KupfermincMJFaitGManyA. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy. 2001; 20(1): 35-44.
9.
GrandoneEBrancaccioVColaizzoBS. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril. 2002; 78(2): 371-375.
10.
LeducLDuboisETakserL. Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. J Obstet Gynaecol Can. 2007; 29(10): 787-793.
11.
PaidasMKuDHTricheELockwoodCArkelY. Does heparin therapy improve pregnancy outcome in patients with thrombophilias?J Thromb Haemost. 2004; 2(7): 1194-1195.
12.
ReyEGarneauPDavidM. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost. 2009; 7(1): 58-64.
13.
KupfermincMRimonEManyAMaslovitzSLessingJBGamzuR. Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia. Blood Coagul Fibrinolysis. 2011; 22(2): 123-126.
14.
MelloGParrettiEFatiniC. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension. 2005; 45(1): 86-91.
15.
KaandorpSPGoddijnMvan der PostJAM. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010; 362(17): 1586-1596.
ClarkPWalkerIDLanghorneP; Scottish Pregnancy Intervention Study (SPIN) collaborators. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood2010; 115(21): 4162-4167.
18.
FawzyMShokeirTEl-TatongyMWardaOEl-RefaieyAAMosbahA. Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Arch Gynecol Obstet. 2008; 278(1): 33-38.
19.
SmithGCSmithMFMcNayMBFlemingJE. First-trimester growth and the risk of low birth weight. N Engl J Med. 1998; 339(25): 1817-1822.
GenbacevODPrakobpholAFoulkRA. Trophoblast L-selectin-mediated adhesion at the maternal-fetal interface. Science. 2003; 299(5605): 405-408.
22.
LaskyLA. Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science. 1992; 258(5084): 964-969.
23.
McEverRPCummingsRD. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest. 1997; 100(11 suppl): S97-S103.
24.
RosenSD. Ligands for L-selectin: homing, inflammation, and beyond. Annu Rev Immunol. 2004; 22: 129-156.
25.
RosenSD. Homing in on L-selectin. J Immunol. 2006; 177(1): 3-4.
26.
StevensonJLChoiSHVarkiA. Differential metastasis inhibition by clinically relevant levels of heparins—correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res. 2005; 11(19 pt 1): 7003-7011.
27.
CavallaroUChristoforiG. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004; 4(2): 118-132.
28.
XueWCFengHCTsaoSW. Methylation status and expression of E-cadherin and cadherin-11 in gestational trophoblastic diseases. Int J Gynecol Cancer. 2003; 13(6): 879-888.
29.
LiHWCheungANTsaoSWCheungALOWS. Expression of e-cadherin and beta-catenin in trophoblastic tissue in normal and pathological pregnancies. Int J Gynecol Pathol. 2003; 22(1): 63-70.
30.
ShihIeMHsuMYOldtRJ 3rd, HerlynMGearhartJDKurmanRJ. The role of E-cadherin in the motility and invasion of implantation site intermediate trophoblast. Placenta. 2002; 23(10): 706-715.
31.
ErdenOImirAGuvenalT. Investigation of the effects of heparin and low molecular weight heparin on E-cadherin and laminin expression in rat pregnancy by immunohistochemistry. Hum Reprod. 2006; 21(11): 3014-3018.
32.
QuenbySMountfieldSCartwrightJEWhitleyGSVinceG. Effects of low molecular weight and unfractionated heparin on trophoblast function. Obstet Gynecol. 2004; 104(2): 354-361.
33.
BenirschkeKKaufmannPBaergenRN. Pathology of the Human Placenta. New York, NY: Springer; 2006.
34.
KhongTYDe WolfFRobertsonWBBrosensI. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynecol. 1986; 93(10): 1049-1049.
35.
BurtonGJJauniauxE. Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol Investig. 2004; 11(6): 342-352.
36.
GanapathyRWhitleyGSCartwrightJEDashPRThilaganathanB. Effect of heparin and fractionated heparin on trophoblast invasion. Hum Reprod. 2007; 22(9): 2523-2527.
37.
Di SimoneNDi NicuoloFSanguinettiM. Low-molecular weight heparin induces in vitro trophoblast invasiveness: role of matrix metalloproteinases and tissue inhibitors. Placenta. 2007; 28(4): 298-304.
38.
BrosensIARobertsonWBDixonHG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu. 1972; 1: 177-191.
39.
Di FedericoEGenbacevOFisherSJ. Preeclampsia is associated with widespread apoptosis of placental cytotrophoblasts within the uterine wall. Am J Pathol. 1999; 155(1): 293-301.
40.
AllaireADBallengerKAWellsSRMcMahonMJLesseyBA. Placental apoptosis in preeclampsia. Obstet Gynecol. 2000; 96(2): 271-276.
41.
NaickerTKhedunSMMoodleyJPijnenborgR. Quantitative analysis of trophoblast invasion in preeclampsia. Acta Obstet Gynecol Scand. 2003; 82(8): 722-729.
42.
BrosensJJPijnenborgRBrosensIA. The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature. Am J Obstet Gynecol. 2002; 187(5): 1416-1423.
43.
LeachREKhalifaRRamirezND. Multiple roles for heparin-binding epidermal growth factor-like growth factor are suggested by its cell-specific expression during the human endometrial cycle and early placentation. J Clin Endocrinol Metab. 1999; 84(9): 3355-3363.
44.
RaabGKlagsbrunM.Heparin bindingEGFgrowth factor. Effects of aPL on trophoblasts via inhibition of HB-EGF expression. Biochim Biophys Acta. 1997; 1333(3): 179-199.
45.
BlotnickSPeoplesGEFreemanMREberleinTJKlagsbrunM. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4 + and CD8 + T cells. Proc Natl Acad Sci USA. 1994; 91(8): 2890-2894.
OngusahaPPKwakJCZwibleAJ. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res. 2004; 64(15): 5283-5290.
48.
RedmanCWSargentIL. Latest advances in understanding preeclampsia. Science. 2005; 308(5728): 1592-1594.
49.
LeachREKilburnBWangJLiuZRomeroRArmantDR. Heparin-binding EGF-like growth factor regulates human extravillous cytotrophoblast development during conversion to the invasive phenotype. Dev Biol. 2004; 266(2): 223-237.
50.
ThompsonSAHigashiyamaSWoodK. Characterization of sequences within heparinbinding EGF-like growth factor that mediate interaction with heparin. J Biol Chem. 1994; 269(4): 2541-2549.
51.
Di SimoneNMaranaRCastellaniR. Decreased expression of Heparin-binding epidermal growth factor–like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. Arthritis Rheum. 2010; 62(5): 1504-1512.
52.
IsakaKUsudaSItoH. Expression and activation of matrix metalloproteinase 2 and 9 in human trophoblasts. Placenta. 2003; 24(1): 53-64.
53.
LibrachCLWerbZFitzgeraldML. 92-kDa type IV collagenase mediates invasion of human cytotrophoblasts. J Cell Biol. 1991; 113(2): 437-449.
54.
Straszewski-ChavezSLAbrahamsVMMorG. The role of apoptosis in the regulation of trophoblast survival and differentiation during pregnancy. Endocr Rev. 2005; 26(7): 877-897.
55.
SmithSCBakerPNSymondsEM. Increased placental apoptosis in intrauterine growth restriction. Am J Obstet Gynecol. 1997; 177(6): 1395-1401.
56.
LeungDNSmithSCToKFSahotaDSBakerPN. Increased placental apoptosis in pregnancies complicated by preeclampsia. Am J Obstet Gynecol. 2001; 184(6): 1249-1250.
57.
IshiharaNMatsuoHMurakoshiHLaoag-FernandezJBSamotoTMaruoT. Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol. 2002; 186(1): 158-166.
58.
ChoiHKChoiBCLeeSHKimJWChaKYBaekKH. Expression of angiogenesis-and apoptosis-related genes in chorionic villi derived from recurrent pregnancy loss patients. Mol Reprod Dev. 2003; 66(1): 24-31.
59.
HillsFAAbrahamsVMGonzález-TimónB. Heparin prevents programmed cell death in human trophoblast. Mol Hum Reprod. 2006; 12(4): 237-243.
60.
TwuCLiuNQPopikW. Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion-and death receptor-controlled pathways. Proc Natl Acad Sci U S A. 2002; 99(22): 14386-14391.
61.
IshikawaYKitamuraM. Inhibition of glomerular cell apoptosis by heparin. Kidney Int. 1999; 56(3): 954-963.
62.
BosePBlackSKadyrovM. Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro. Am J Obstet Gynecol. 2004; 191(6): 2125-2131.
63.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2): 295-306.
64.
WoodhamsBJCandottiGShawRKernoffPB. Changes in coagulation and fibrinolysis during pregnancy: evidence of activation of coagulation preceding spontaneous abortion. Thromb Res. 1989; 55(1): 99-107.
65.
ChamleyLW. Action of anticardiolipin andantibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet. 1998; 352(9133): 1037-1038.
66.
FranklinRDKuttehWH. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. Obstet Gynecol. 2003; 101(3): 455-462.
67.
OutHJKooijmanCDBruinseHWDerksenRH. Histopathological findings in placentae from patients with intrauterine fetal death and antiphospholipid antibodies. Eur J Obstet Gynecol Reprod Biol. 1991; 41(3): 179-186.
68.
SebireNJFoxHBackosMRaiRPatersonCReganL. Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum Reprod. 2002; 17(4): 1067-1071.
69.
LydenTWVogtENgAKJohnsonPMRoteNS. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast. J Reprod Immunol. 1992; 22(1): 1-14.
70.
SthoegerZMMozesETartakovskyB. Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. Proc Natl Acad Sci U S A. 1993; 90(14): 6464-6467.
71.
Di SimoneNMeroniPLDel PapaN. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta-2-glycoprotein I. Arthritis Rheum. 2000; 43(1): 140-150.
72.
OrnoyAYacobiSMatalonST. The effects of antiphospholipid antibodies obtained from women with SLE/APS and associated pregnancy loss on rat embryos and placental explants in culture. Lupus. 2003; 12(7): 573-578.
73.
Di SimoneNFerrazzaniSCastellaniR. Heparin and low dose aspirin restore placental human chorionic gonadotrophin secretion abolished by antiphospholipid antibody-containing sera. Hum Reprod. 1997; 12(9): 2061-2065.
74.
Di SimoneNCaliandroDCastellaniRFerrazzaniSDe CarolisSCarusoA. Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. Hum Reprod. 1999; 14(2): 489-495.
75.
GuerinJShengYReddelSIversonGMChapmanMGKrilisSA. Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome. J Biol Chem. 2002; 277(4): 2644-2649.
76.
HorbachDAvan OortELismanTMeijersJCDerksenRHde GrootPG. Beta2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb Haemost. 1999; 81(1): 87-95.
77.
GirardiGBermanJRedechaP. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003; 112(11): 1644-1654.
78.
GirardiGRedechaPSalmonJE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004; 10(11): 1222-1226.
79.
FriedrichsGSKilgoreKSManleyPJGralinskiMRLucchesiBR. Effect of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart. Circ Res. 1994; 75(4): 701-710.
80.
KoenigANorgard-SumnichtKLindhardtRVarkiA.Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest. 1998; 101(4): 877-889.
81.
WangLBrownJRVarkiAEskoJD. Heparin’s anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L-and P-selectins. J Clin Invest. 2002; 110(1): 127-136.
82.
RopsALvan der VlagJJacobsCW. Heparan sulphate proteoglycans in glomerular inflammation. Kidney Int. 2004; 65(3): 768-785.
83.
MollnesTEBrekkeOLFungM. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood. 2002; 100(5): 1869-1877.
84.
HochartHJenkinsPVSmithOPWhiteB. Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. Br J Haematol. 2006; 133(1): 62-67.
85.
BermanJGirardiGSalmonJE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol. 2005; 174(1): 485-490.
